Background: African-American (AA) men tend to present with more aggressive
binds the vitamin D receptor (VDR) that allows VDR to bind to specific DNA motifs of its target genes, such as p21 and p27. 3, 4 Alterations in components of vitamin D metabolism, which include polymorphisms in the hydroxylase enzymes, can lead to varying serum vitamin D metabolite levels in individuals from different ethnic cohorts. [5] [6] [7] [8] African-American (AA) men and women usually present with low 25(OH)D levels compared with their European-American (EA) counterparts, 9-11 even though 1,25(OH) 2 D levels are similar by race. 12 Skin pigmentation, decreased consumption of dairy products and fortified foods, lack of vitamin D supplementation, and elevated body mass index (BMI) have been related to low 25(OH)D levels in AAs. 11, 13 AA men are more likely to be diagnosed with and/or die from aggressive prostate cancer than EA men. 14 
| MATERIALS AND METHODS

| Study population
A subset of research subjects from the North Carolina-Louisiana Prostate Cancer Project (PCaP) 25 was included in this study. A subset of n = 1000 research subjects who agreed to future use of their biological specimens were selected a priori. 
| Data collection
A trained registered nurse conducted structured interviews, collected necessary specimens and measurements of research subjects at their home within 4 months of initial diagnosis, on average.
Structured interviews were performed using a questionnaire that included a family history of prostate cancer, cancer screening history and vitamin supplementation among other variables listed in Table 1 .
The National Cancer Institute Diet History Questionnaire modified to accommodate Cajun, and Creole foods were used to inform about food portion sizes and intake frequency for a list of 124 food items.
The Diet*Calc software was used to calculate the intake of nutrients and minerals including calcium and vitamin D. 
| Outcome assessment
In PCaP, research subjects were categorized into the following three categories of aggressiveness 25 : (1) High aggressive cases:
Gleason sum ≥ 8, or PSA > 20 ng/mL at diagnosis, or Gleason sum = 7 and stage T3-T4; (2) low aggressive cases: Gleason sum < 7 and diagnosed at stage T1-T2 and PSA < 10 ng/ml at diagnosis; and (3) 3 | RESULTS
| Demographics of research subjects
AA and EA research subjects in both low and high aggressive prostate cancer had similar representation from NC and LA (46%-50%). Fall interviews (>40%) were more common than the other three seasons.
Less than 20% of AA research subjects had <0.85 African ancestries as determined by ancestry informative markers. At least 60% of EA and AA research subjects had high school-level education, but less than 10%
of AA and 25% of EA research subjects had a graduate or professional degree. A higher percentage of EA research subjects were married or living with a partner compared with AA research subjects (19% and 12% difference in low and high aggressive categories, respectively). A greater percent of AA research subjects were current smokers compared with EA research subjects in both aggressiveness categories.
In low aggressive prostate cancer, AA and EA research subjects had a similar family history of prostate cancer. However, in high aggressive prostate cancer, a higher proportion of AA research subjects had a family history of prostate cancer compared with EA research subjects.
More AA research subjects had not been screened than EA research subjects in the high aggressive category.
| Increased plasma 1,25(OH) 2 D levels associated with reduced odds of high aggressive prostate cancer in AA and EA men
Mean plasma levels of 1,25(OH) 2 D were similar between low aggressive AA (28.0 ± 8.7 pg/mL) and EA (29.3 ± 9.1 pg/mL) research subjects and high aggressive AA (27.7 ± 9.3 pg/mL) and EA (27.6 ± 9.3 pg/mL) research subjects ( Figure 1A ). Multivariable-adjusted odds ratios in both AA and EA research subjects indicated that higher 1,25(OH) 2 D levels in the plasma were associated with reduced odds of high aggressive prostate cancer, though confidence intervals included the null (Table 2) , and there was no evidence of a dose-response association. (Table 4 ). In EA research subjects, crude and adjusted OR did not show dramatic reductions in high aggressive prostate cancer with increasing molar ratio (Table 4) . Only the fourth quartile of molar ratio (greater than However, a phase III ASCENT trial using a combination of docetaxel and calcitriol for castrate-resistant prostate cancer patients was terminated due to reduced survival compared with the placebo arm. 31 Earlier trials that used docetaxel once every 3 weeks showed superior survival rates compared with weekly docetaxel. 31 Therefore, the authors suggested that weekly docetaxel schedule and not calcitriol was the possible reason for reduced survival in the treatment arm compared with the placebo arm. 
T A B L E 4 Association between molar ratio of plasma 1,25(OH) 2 D to 25(OH)D and prostate cancer aggressiveness by race
